Canine Comprehensive Genomic Profiling (Canine CGP) test performs whole exome sequencing of canine tumors, investigating all common mutation types in over 20,257 coding genes across the canine genome. Canine CGP is the world’s largest, most comprehensive tumor genomic diagnostic test for dogs with cancer, providing unparalleled insights into tumor genomics to support personalized cancer management and effective treatment.
Canine CGP provides genomics-based treatment recommendations for all targeted therapy, immunotherapy, chemotherapy, and radiation therapy that are currently available for dogs’ use, a first-of-its-kind test in veterinary medicine.
Our Approach
Let data drive advancements: every case we manage contributes valuable insights to improve outcomes for the next dog.
- Comprehensive Genomic Profiling: Canine CGP provides detailed, unbiased insights into the genomic landscape of every cancer type and each dog’s cancer.
- Hypothesis-driven Clinical Studies: We hypothesize that the human-inferred biomarker-drug evidence provides a foundation to guide genomic-based treatments in dogs. Leveraging our comprehensive genomic profiling and the real-world clinical data — such as treatment regimens, response types, progression-free survival, overall survival — from our patients, we assess the validity of this translational evidence and the impact of genomic-based treatments in dogs with cancer.
- Advanced AI Modeling: We utilize AI to connect individual dog data points, uncovering complex patterns and trends across diverse genomic and clinical profiles, which will enable us to identify the most effective therapies for each type or subtype of cancer and individual dog.
- Drug development and repurposing: Our genomic data and clinical data will guide the development of new drugs, or repurposing, or prioritization of existing drugs.